Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. is experiencing strong growth momentum with its leading product, Cabometyx, particularly in the first-line renal cell carcinoma (1L RCC) and the expanding second-line neuroendocrine tumor (2L+ NET) markets, which is supported by an increase in market share to 46% in the TRx market. The company is strategically expanding its gastrointestinal sales team to capitalize on this demand and to prepare for the launch of zanzalintinib for colorectal cancer (CRC), further enhancing its product offerings. Additionally, Exelixis maintains a strong balance sheet and has updated its sales estimates for Cabometyx to reflect continued growth, indicating a positive outlook for the company’s financial health and profitability in the coming years.

Bears say

Exelixis Inc. has presented several challenges that contribute to a negative outlook on its stock, most notably a decrease in gross-to-net (GTN) from 30.2% in 3Q25 to 28.5% in 4Q25, attributed to reduced PHS/340B volume. Sales for Cabometyx remained flat sequentially at $545 million, underperforming against estimates, which raises concerns regarding the potential for growth amid increasing competition in the renal cell and hepatocellular carcinoma markets. Additionally, risks related to commercial performance of Cabometyx, the failure to yield favorable data from ongoing clinical trials, and looming challenges from generic competition further exacerbate uncertainties surrounding Exelixis's financial stability and long-term viability.

Exelixis (EXEL) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 16 analysts, Exelixis (EXEL) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.